Daily Archives: January 18, 2018
P156 REDUCTION IN THE PREVALENCE OF ANEMIA AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE AFTER IMPLEMENTATION OF THE ANEMIA CARE PATHWAY
Anemia is a common but under-recognized complication of inflammatory bowel diseases (IBD). Anemia in IBD is associated with increased resource utilization and reduced quality of life, yet screening and management of anemia among IBD patients is poor. T… Continue reading
Posted in News
Comments Off on P156 REDUCTION IN THE PREVALENCE OF ANEMIA AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE AFTER IMPLEMENTATION OF THE ANEMIA CARE PATHWAY
14 POST-HOC ANALYSIS OF TOFACITINIB CROHN’S DISEASE PHASE 2 INDUCTION EFFICACY IN SUBGROUPS WITH BASELINE ENDOSCOPIC OR BIOMARKER EVIDENCE OF INFLAMMATION
Tofacitinib is an oral, small molecule Janus kinase (JAK) inhibitor that is being investigated for IBD. In a recent trial of Crohn’s disease (CD) patients (pts), small treatment effects for tofacitinib vs placebo (PBO) were noted using CD Activity In… Continue reading
Posted in News
Comments Off on 14 POST-HOC ANALYSIS OF TOFACITINIB CROHN’S DISEASE PHASE 2 INDUCTION EFFICACY IN SUBGROUPS WITH BASELINE ENDOSCOPIC OR BIOMARKER EVIDENCE OF INFLAMMATION
P163 TRANSITION TO BIOLOGIC HOME INFUSIONS IN IBD PATIENTS IS ASSOCIATED WITH HIGH DROP OUT WITHIN ONE YEAR
Optimal inflammatory bowel disease (IBD) therapy often requires biologic medications delivered by intravenous (IV) infusion. Until recently, infusions were generally delivered in supervised hospital or outpatient clinics. As insurance companies attempt… Continue reading
Posted in News
Comments Off on P163 TRANSITION TO BIOLOGIC HOME INFUSIONS IN IBD PATIENTS IS ASSOCIATED WITH HIGH DROP OUT WITHIN ONE YEAR
P168 WHERE WILL FECAL MICROBIOTA TRANSPLANTATION FIT IN THE TREATMENT ALGORITHMS FOR CROHN’S DISEASE AND ULCERATIVE COLITIS: A SYNTHESIS OF COMPLETED, ONGOING AND FUTURE TRIALS
The United States Food and Drug Administration (FDA) exercises enforcement discretion for fecal microbiota transplantation (FMT) for Clostridium difficile infection not responsive to standard therapies. An investigational new drug (IND) is required for… Continue reading
Posted in News
Comments Off on P168 WHERE WILL FECAL MICROBIOTA TRANSPLANTATION FIT IN THE TREATMENT ALGORITHMS FOR CROHN’S DISEASE AND ULCERATIVE COLITIS: A SYNTHESIS OF COMPLETED, ONGOING AND FUTURE TRIALS
P165 UTILIZATION OF REACTIVE DRUG LEVEL MONITORING IN INFLAMMATORY BOWEL DISEASE
Biologics and thiopurines are standard therapies in the management of Crohn’s disease (CD) and ulcerative colitis (UC). Reactive therapeutic drug concentration monitoring (TDM) provides insights into the mechanism of loss of response and allows effec… Continue reading
Posted in News
Comments Off on P165 UTILIZATION OF REACTIVE DRUG LEVEL MONITORING IN INFLAMMATORY BOWEL DISEASE
P169 A CASE OF SUCCESSFUL INDUCTION OF REMISSION IN MODERATE-TO-SEVERE STEROID REFRACTORY ULCERATIVE COLITIS USING HERBAL THERAPY
The use of Complementary and Alternative Medicine (CAM) is prevalent in patients with ulcerative colitis (UC). Most randomized clinical trials (RCT) of herbal supplements in UC studied inactive or mild-to-moderate UC, and they were small studies. We pr… Continue reading
Posted in News
Comments Off on P169 A CASE OF SUCCESSFUL INDUCTION OF REMISSION IN MODERATE-TO-SEVERE STEROID REFRACTORY ULCERATIVE COLITIS USING HERBAL THERAPY
P167 VEDOLIZUMAB TROUGH LEVELS AND ANTIBODIES IN INFLAMMATORY BOWEL DISEASE: UPDATED INITIAL EXPERIENCE
The utility of vedolizumab (VDZ) trough levels (VTL) in the management of patients with inflammatory bowel disease (IBD) has not been well defined. The aims of this study are to determine: the median VTL and frequency of antibodies, the correlation of … Continue reading
Posted in News
Comments Off on P167 VEDOLIZUMAB TROUGH LEVELS AND ANTIBODIES IN INFLAMMATORY BOWEL DISEASE: UPDATED INITIAL EXPERIENCE
P170 A NOVEL PATIENT REPORTED QUALITY OF LIFE MEASURE CORRELATES WELL WITH THE SHORT INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE IN A LARGE INTERNET BASED COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE
The Short Inflammatory Bowel Disease Questionnaire (SIBDQ), a validated inflammatory bowel disease (IBD) specific measure of health related quality of life (HRQOL), is a proprietary instrument. We aimed to create and evaluate a novel measure of HRQOL a… Continue reading
Posted in News
Comments Off on P170 A NOVEL PATIENT REPORTED QUALITY OF LIFE MEASURE CORRELATES WELL WITH THE SHORT INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE IN A LARGE INTERNET BASED COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE
P164 USING EXOME SEQUENCING TO EXPAND THE GENETIC ARCHITECTURE OF INFLAMMATORY BOWEL DISEASE
IBD studies over the past decade have confirmed association to 250 gene loci. A handful of associations have led to specific validated functional variants highlighting intracellular response to microbes and regulation of adaptive immunity in IBD pathog… Continue reading
Posted in News
Comments Off on P164 USING EXOME SEQUENCING TO EXPAND THE GENETIC ARCHITECTURE OF INFLAMMATORY BOWEL DISEASE
P171 AUTOIMMUNE DISORDERS AFTER PROCTOCOLECTOMY IN ULCERATIVE COLITIS
Inflammatory bowel diseases (IBD), along with other immune-mediated disorders are considered as idiopathic disease entities with no clearly identified etiology. However, they can be triggered by medications, immunotherapy and manipulation of gut microb… Continue reading
Posted in News
Comments Off on P171 AUTOIMMUNE DISORDERS AFTER PROCTOCOLECTOMY IN ULCERATIVE COLITIS